Proxima, the Roivant‑founded drug discovery firm formerly known as VantAI, closed an $80 million seed round to develop AI‑driven proximity‑modulating drugs that target protein‑protein interactions. The financing was oversubscribed and drawn from strategic and venture investors. The company combines proteome‑scale structural datasets with advanced AI models to design molecules that induce or modulate proximity between proteins — an approach relevant to induced‑proximity therapeutics such as degraders and molecular glues. Proxima said it will advance programs in cancer and immunology and scale discovery partnerships with larger biopharma firms. Investors framed the round as validation of AI‑first design for challenging modalities. Proxima’s funding and rebrand signal growing capital appetite for firms that pair structural biology with generative AI to target previously intractable interaction surfaces.